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Available online 1 May 2013Sensitive measurement of multiple cytokine profiles from small mucosal tissue biopsies, for
example human gastric biopsies obtained through an endoscope, is technically challenging.
Multiplex methods such as Luminex assays offer an attractive solution but standard protocols are
not available for tissue samples. We assessed the utility of three commercial Luminex kits
(VersaMAP, Bio-Plex and MILLIPLEX) to measure interleukin-17A (IL-17) and interferon-gamma
(IFNγ) concentrations in human gastric biopsies and we optimised preparation of mucosal
samples for this application. First, we assessed the technical performance, limits of sensitivity and
linear dynamic ranges for each kit. Nextwe spikedhuman gastric biopsieswith recombinant IL-17
and IFNγ at a range of concentrations (1.5 to 1000 pg/mL) and assessed kit accuracy for spiked
cytokine recovery and intra-assay precision. We also evaluated the impact of different tissue
processing methods and extraction buffers on our results. Finally we assessed recovery of
endogenous cytokines in unspiked samples. In terms of sensitivity, all of the kits performed
well within the manufacturers' recommended standard curve ranges but the MILLIPLEX kit
providedmost consistent sensitivity for low cytokine concentrations. In the spiking experiments,
the MILLIPLEX kit performed most consistently over the widest range of concentrations.
For tissue processing, manual disruption provided significantly improved cytokine recovery
over automated methods. Our selected kit and optimised protocol were further validated by
measurement of relative cytokine levels in inflamed and uninflamed gastric mucosa using
Luminex and real-time polymerase chain reaction. In summary, with proper optimisation
Luminex kits (and for IL-17 and IFNγ theMILLIPLEX kit in particular) can be used for the sensitive
detection of cytokines in mucosal biopsies. Our results should help other researchers seeking
to quantify multiple low concentration cytokines in small tissue samples.






Assessing cytokine profiles in small tissue biopsies presents
a significant technical challenge, particularly the quantificationSciences, University of
K. Tel.: +44 115 823
(K. Robinson).
r B.V. Open access under CC BYof multiple cytokines when some are present at low concen-
trations. Multiplex methods using Luminex technology may
offer an attractive solution. However these are often developed
using solublematerials such as sera or cell culture supernatants
spiked with recombinant cytokines and standard protocols are
not available for tissue samples. Luminex assays use multiple
sets of polystyrene or paramagnetic beads or ‘microspheres’ —
see Vignali (2000) and Houser (2012). Each set is fluores-
cently colour-coded to be identifiable on a dedicated flow
cytometer or other platform and pre-coated with antibody
to capture a specific cytokine or other analyte, around which
a sandwich immunoassay is built. Different bead sets can be license.
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cytokine concentrations in a single sample against standard
curve preparations. These assays require substantially less
sample than traditional enzyme-linked immunosorbent assays
(ELISAs) – typically 25–50 μL for multiple analytes compared
with 200 μL for a single analyte – yet may offer similar
sensitivity to Luminex (Vignali, 2000; Biagini et al., 2004;
Elshal and McCoy, 2006).
Our research concerns the characterisation of immune
responses to the pathogen Helicobacter pylori (Hp) which are
linked to peptic ulceration and gastric cancer development
(Atherton, 2006; Robinson et al., 2008). The challenges are
broadly similar in other fields, particularly for gastrointestinal
mucosal researchers: how to study immune responses using
methodology that better reflects cytokine levels in the mucosa
in vivo. Endoscopic mucosal biopsies are small (typically
around 5–10 mg) and concentrations of many of the cytokines
of interest are low, so assay sensitivity and sample volume
requirements are critical. Other investigators have used
semi-quantitative methods including immunohistochemistry
(Lindholm et al., 1998; Lehmann et al., 2002; Holck et al., 2003)
andwestern blotting (Luzza et al., 2000; Tomita et al., 2001), or
PCR-based methods to quantify cytokine mRNA which are not
always fully reflected at the protein level (Luzza et al., 2001;
Robinson et al., 2008; Serelli-Lee et al., 2012). Cytokines have
been measured in gastric biopsy homogenates using ELISA
(Yamaoka et al., 2001; Shimizu et al., 2004; Caruso et al., 2008;
Robinson et al., 2008; Serelli-Lee et al., 2012), but additional
volume is needed for each analyte assayed which may require
sample dilution. Therefore the number of cytokines, particu-
larly those present at low concentrations, that can be assayed
using this method is limited. Another common approach is
to culture gastric biopsies in vitro, with or without stimula-
tion, and measure cytokine concentrations in culture super-
natants (Crabtree et al., 1991; Bodger et al., 1997; Mizuno
et al., 2005). However, these methods may alter the cytokine
profile (Veldhoen et al., 2009). The cytokine concentrations in
homogenates of gastric biopsies should more closely reflect
those found in the gastric mucosa in vivo.
Luminex-based methods have been used to assess murine
immune responses to Hp infection (Taylor et al., 2008) and
vaccination (Taylor et al., 2007) in splenocyte culture
supernatant and recently to quantify gastric cytokine con-
centrations in Hp-infected mice (Schumacher et al., 2012). A
method to measure Hp-specific IgG in human saliva samples
has also been developed, using Luminex beads conjugated
with antigens including Hp whole cell sonicate and recombi-
nant urease (Griffin et al., 2011). However, to our knowledge,
Luminex assays have not been optimised for human gastro-
intestinal mucosal tissue samples, though were recently used
to quantify interleukin-1β, interleukin-1 receptor antagonist,
interleukin-6 and tumour necrosis factor-α in gastric tissue
samples (Serelli-Lee et al., 2012). Careful kit selection and
optimisation of tissue sample preparation in a limited volume
of extraction buffer will theoretically facilitate cytokine detec-
tion in these samples.
Here we aim to systematically compare and contrast the
accuracy and performance of several commercially available
Luminex assays as well as different sample homogenisation
protocols for quantification of cytokines in tissue biopsies.
We purchased assays from three suppliers: Bio-Plex Pro(Bio-Rad Laboratories, CA, USA), MILLIPLEX MAP (Merck
Millipore, Darmstadt, Germany) and VersaMAP (R&D Sys-
tems, MN, USA) with assays for interleukin-17A (IL-17) and
interferon-gamma (IFNγ). This evaluation using cytokine
spiked human gastric biopsies provides more widely rele-
vant information on the technology's ability to quantify
cytokines present at low concentrations in small tissue
samples and optimisation of mucosal tissue preparation for
this application. Finally we report on the suitability of our
selected Luminex kit and optimised homogenisation proto-
col to detect endogenous cytokines in uninfected and
Hp-infected clinical samples.
2. Materials and methods
2.1. Patients and samples
Patients attending for clinically-indicated routine upper
gastrointestinal endoscopy at Queen's Medical Centre
(Nottingham, UK) donated additional gastricmucosal biopsies
for research. These were immediately snap frozen in liquid
nitrogen and stored at −80 °C. Patients were ineligible for
inclusion in the study if they had previous gastric surgery, were
regularly taking non-steroidal anti-inflammatory drugs (those
taking regular aspirin for cardiovascular prophylaxis were
not excluded), regular steroids or other immunosuppressive
therapy, or had taken antibiotics in the preceding four weeks
or proton pump inhibitors in the preceding twoweeks.Written
informed consent was obtained from all participants after the
nature and possible consequences of the studies had been
fully explained. Ethical approval was granted by the National
Research Ethics Service East Midlands — Nottingham 2
Committee (08/H0408/195).
For the kit and tissue processing comparisons, seven
patients (mean age ± standard deviation (SD) [range];
51 ± 19 years [21–69]; two male, five female) each donated
nine antral biopsies which were stored for up to 10 weeks
until sample preparation. For evaluation of uninfected and
Hp-infected tissue by Luminex cytokine assays, antral biopsies
from a further 24 patientswere used (51 ± 15 years [17–75];
13 male, 11 female) of whom 18 were Hp+ and none of
the six Hp− patients had evidence of gastric inflammation
by histology. To determine mRNA expression we used antral
biopsies from a further 41 consecutive patients (51 ± 15 years
[29–81]; 17 male, 24 female) such that each transcript was
evaluated in 18 Hp+ and 6 Hp− patients as complete data
were not available for every patient. Hp status was assessed by
biopsy urease test, culture, histology and IgG serology, with
patients classified as infected if supported by at least three
parameters and non-infected if all four parameters were
negative with no history of previous eradication therapy.
2.2. Sample preparation methods
Single biopsies from each patient were individually thawed
on ice then immediately disrupted in extraction buffer, either:
(1) manually with a mini pellet pestle (Kimble Kontes, NJ,
USA) for 2 min, (2) a proportion of those disrupted by pestle
were further homogenised by 5–10 repeated passes through
a 23 G needle and 1 mL syringe, or (3) automatically with a
bead-basher (TissueLyser LT, QIAGEN, Hilden, Germany) using
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for 3 min. Extraction buffer comprised either: (A) RPMI-1640
(Sigma-Aldrich, MO, USA) supplemented with 10% (v/v) fetal
calf serum (FCS, heat-inactivated, Sigma-Aldrich), (B)
phosphate-buffered saline (PBS, pH 7.4, Dulbecco A, Oxoid,
Basingstoke, UK), or (C) PBS supplemented with 2 mM Mg2+
(Sigma-Aldrich) and benzonase endonuclease (at 25 U/mL,
>90% pure, Novagen, Darmstadt, Germany). Protease inhibi-
tors (cOmplete mini [EDTA-free], Roche, Basel, Switzerland)
were included in each extraction buffer. After disruption/
homogenisation, all sampleswere incubated on ice for 5 min to
allow sufficient time for viscosity reduction in endonuclease-
supplemented samples. Finally, supernatants were obtained by
centrifugation at 10,000 ×g for 10 min at 4 °C, spiked and split
into aliquots as required (see below), and stored in Protein
LoBind tubes (Eppendorf, Hamburg, Germany) at−80 °C until
analysis.
We also evaluated two commercial kits that extract
proteins from tissue samples in accordance with the manu-
facturers' instructions (NucleoSpin TriPrep, Macherey-Nagel,
Düren, Germany; RNA/DNA/Protein Purification Plus Kit,
Norgen Biotek, ON, Canada) but found that the resulting
protein samples interferedwith Luminex assay function (data
not shown).
2.3. Cytokine spiking of samples
To assess kit performance and accuracy, nine biopsies each
from three patients were individually prepared using method
(1) and extraction buffer (A). 50 μL of each of the resulting
supernatants for each patient were combined (to give a total
volume of 450 μL per patient), then split into three aliquots
and spiked with 15 μL of known concentrations of both
recombinant human IL-17 and IFNγ (eBioscience, CA, USA)
diluted in extraction buffer (A). Cytokine spikes were at final
concentrations of 0.0 (“unspiked”), 1.5, 6.0, 50.0, 100.0 and
1000.0 pg/mL. A single technical replicate was included in
each run.
Biopsies from a further four patientswere used to optimise
processing methods and assess repeatability (intra-assay
precision). Biopsies were processed using methods (1), (1)
and (2), or (3) in 600 μL of PBS-based extraction buffer (B)
or (C). Multiple pairs of biopsies from each patient were
spiked prior to processing, either with recombinant human
IL-17 and IFNγ (Merck Millipore) at a final concentration of
100.0 pg/mL in extraction buffer or with extraction buffer
alone (“unspiked”). At least two technical replicates for each
sample were included in each run. Cytokine recovery was
adjusted for background cytokine concentrations from
the unspiked samples and the different processing methods
were compared. Repeatability was assessed using four techni-
cal replicates each from three of these samples, included at
different positions on the same assay plate. The coefficient of
variation (%CV) was calculated for each as [SD / mean] × 100.
2.4. Luminex cytokine assays and data analysis
Assays were run according to each manufacturer's in-
structions. The VersaMAP and Bio-Plex kits used non-magnetic
beads (5.6 μm diameter) and the MILLIPLEX kit used para-
magnetic beads (6.5 μm diameter). Filter plates and vacuumwashing were used for all three kits for comparison. Standards
were assayed in duplicate as provided by each manufacturer
and standard curves extended down to b1.0 pg/mL with
additional steps. For subsequent assessment of endogenous
cytokines in unspiked samples we used MILLIPLEX kits. Assays
were run as per manufacturers' instructions with standards
and samples in duplicate, overnight incubationwith shaking at
4 °C (18 h, 750 rpm) and using a hand-held magnetic block
for wash steps.
Data were acquired on a validated and calibrated Bio-Plex
200 system (Bio-Rad) and analysed with Bio-Plex Manager
6.0 software (Bio-Rad) with a detection target of 50 beads
per region, low RP1 target for CAL2 calibration, and
recommended doublet discriminator (DD) gates of 5000–
25,000 for Bio-Plex and MILLIPLEX kits and 4300–10,000 for
the VersaMAP kit. Standard, control and sample wells with
bead counts b37 were excluded as at least this number is
required to minimise the potential impact of outlier beads on
median fluorescence intensity (MFI). We excluded from the
standard curve any points with %CV b25% and those with
accuracy outside of 80–120% of expected were excluded
starting from the lowest standard. The analysis software was
then used to fit a curve to this set of reliable standards data
using five parameter logistic regressionwith default automated
weighting (all fitted to ≥6 points). A similar standard curve
optimisation process is now incorporated into the latest
software release and was used for experiments to assess
endogenous cytokines in clinical samples.
Lower and upper limits of quantification (LLOQ and
ULOQ) were calculated as the highest and lowest measured
reliable standards for each standard curve after optimisation
as above. The linear dynamic range (LDR) was defined as the
lowest and highest standards on the linear part of each
standard curve on a log–log plot. Additional experimental
readouts were spiked cytokine recovery (measure of accuracy,
[observed concentration / expected concentration] × 100, ac-
ceptance criteria ± 20%), repeatability (measure of intra-assay
precision, %CV, acceptance criteria b25%) and total protein
recovery using a bicinchoninic acid (BCA) assay kit (Pierce,
IL, USA).
2.5. Real-time reverse transcriptase polymerase chain reaction
(RT-qPCR)
Gastric biopsies were transferred at endoscopy to RNAlater
solution (Sigma-Aldrich) and preserved at −80 °C. Total
RNA was extracted after homogenisation with a TissueRuptor
rotor–stator using an AllPrep DNA/RNA mini kit (QIAGEN).
RNA concentration and puritywere assessed using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, DE,
USA) and integrity assessed using an Agilent 2100 Bioanalyzer
microfluidic platform (Agilent Technologies, CA, USA). After
DNase treatment with Ambion Turbo DNA-free kit (Applied
Biosystems, CA, USA), cDNAwas synthesised using SuperScript
II reverse transcriptase with hexamer random primers (both
Invitrogen, CA, USA). Quantification of mRNA transcripts of
IL17A, IFNG, IL8 and the reference gene GAPDHwas performed
using DyNAmo SYBR Green PCR master mix (Finnzymes,
Thermo Fisher Scientific, MA, USA) on a Corbett Rotor Gene
3000 system (QIAGEN). Amplification was carried out in
triplicate over 40 to 45 cycles of 15 s at 95 °C, 30 s at 61 °C
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Included in each assaywere commercial human cDNA (Clontech,
BD Biosciences, CA, USA) positive controls, no template controls
and first-stage RT minus controls. Specificity analysis was
performed with high resolution melt curves. Results were
analysed by Pfaffl's relative quantification method (Pfaffl,
2001), normalising against GAPDH and comparing against a
pooled negative comparator prepared from a further 14
uninfected donors. Commercial primers were used for IL17A
and IFNG (SABiosciences, QIAGEN). IL8 primers were F:
5′-CTCTTGGCAGCCTTCCTGA and R: 5′-AGTTCTTTAGCACTCCTT
GGCA. GAPDH primers were as previously described (Robinson
et al., 2008). Data were analysed with Rotor-Gene software
(version 6.1, Corbett Research, UK).
2.6. Statistical analysis
Statistical analysis was performed using Prism 6.00
(GraphPad, Software CA, USA). Continuous variables were
compared using non-parametric Mann–Whitney U-tests.
Two-tailed p b 0.05 was considered significant.
3. Results
3.1. Sensitivity, standard curves and technical considerations
One of our objectives was to assess cytokines present
at low concentrations and therefore the performance of
the three Luminex kits in terms of their sensitivity and
assay range. Standard curves provided by each manufacturer
were run as recommended but extended to b1.0 pg/mL to
further assess kit sensitivity. As expected all kits performed
well within the standard curve ranges recommended by
each manufacturer (Table 1), although the Bio-Plex kit was
less sensitive for IFNγ in our hands with a lower limit
of quantification (LLOQ) of 8.1 pg/mL (vs 1.9 pg/mL lowest
recommended standard). The VersaMAP kit had the lowest
LLOQ for IFNγ (0.3 pg/mL) although the lowest recommended
standard for this kit was 27.2 pg/mL. For IL-17, the Bio-Plex kit
was most sensitive with a LLOQ of 1.3 pg/mL. Overall theTable 1
Lower limit of quantification (LLOQ), upper limit of quantification (ULOQ)
linear dynamic range (LDR) and standard curves for the three kits tested for
interleukin-17A (IL-17) and interferon-gamma (IFNγ). Standard curves
shown are based on extended dilution series with figures in brackets
showing lower and upper limits suggested by each manufacturer where










IL-17 VersaMAP 5.9 4643.2 5.9 4643.2 0.2
(19.0)
4616.0
Bio-Plex 1.3 23,036.0 1.3 5120.4 0.3
(1.3)
21,505.0




IFNγ VersaMAP 0.3 5753.6 1.0 2397.6 0.3
(27.2)
6620.0
Bio-Plex 8.1 30,659.5 26.5 7660.5 0.5
(1.9)
30,646.0
MILLIPLEX 2.8 9143.7 2.8 9143.7 0.2
(3.2)
9000.0
(10,000.0),MILLIPLEX kit performed closest to the specified product
characteristics for both analytes. In addition though the upper
limits of quantification (ULOQ) were highest with the Bio-Plex
kit, the MILLIPLEX kit provided the broadest linear dynamic
ranges.
Low bead counts for a particular well can reduce confidence
in the reported median fluorescence intensity and hence
the analyte concentration value interpolated from a standard
curve.Manufacturers generally validate their assayswith soluble
materials such as sera, plasma and cell culture supernatants. We
therefore assessed kit performance with our samples— clarified
supernatants from disrupted and homogenised mucosal tissue.
Low bead counts were more common with the VersaMAP
kit in our hands (>90% of samples on some runs and up to 1 in
3 standard/control wells). In contrast for the Bio-Plex and
MILLIPLEX kits, low bead counts were not observed in any
standard/control wells and in 11% and 1% of samples respec-
tively. This may have been a result of greater median bead
aggregation observedwith this type of sample for the VersaMAP
kit than for the Bio-Plex and MILLIPLEX kits (29% vs 11% and
12% respectively).
Even though each kit performed as specified and intended
by the manufacturers, our aim was to quantify low concen-
trations of both IL-17 and IFNγ in tissue samples. Given our
findings for sensitivity, standard curves and technical perfor-
mance, only the Bio-Plex and MILLIPLEX kits were evaluated
further.
3.2. Spiked cytokine recovery (accuracy)
Spiked cytokine recovery was used to measure the ability
of each kit to accurately quantify recombinant cytokines
in tissue homogenates. Nine biopsies each from three
patients were individually prepared by manual disruption
in extraction buffer (A). Supernatants from each patient were
combined and split into aliquots. For each set of aliquots from
a single patient, one was spiked with extraction buffer alone
(“unspiked”) and two were spiked with known concentra-
tions of both recombinant human IL-17 and IFNγ. Therefore
we evaluated the ability of each of the kits to accurately
measure cytokine spikes in mucosal tissue homogenates
at lower and higher concentrations (1.5, 6, 50, 100 and
1000 pg/mL; for range of standard curves see Table 1).
Observed IL-17 values were lower than expected for both
the Bio-Plex kit (≥6 pg/mL: 38% ± 8% [mean ± SD], 29–47%
[range]) and the MILLIPLEX kit (≥6 pg/mL: 36% ± 12%, 21–
49%) — see Fig. 1A. Neither kit adequately measured IL-17
spike recovery at 1.5 pg/mL. The background levels in
unspiked samples from the three patients were 0.0, 0.0 and
1.8 pg/mL for the Bio-Plex kit and slightly higher at 0.0, 2.4
and 2.5 pg/mL for the MILLIPLEX kit.
The IFNγ spikes were recovered with generally lower
than expected accuracy using the MILLIPLEX kit (≥50 pg/mL:
32% ± 12%, 19–42%) and overall with higher than expected
accuracy with the Bio-Plex kit (≥50 pg/mL: 218% ± 235%,
57–487%) — see Fig. 1B. Neither kit adequately measured
IFNγ spike recovery at 1.5 pg/mL and only the MILLIPLEX
kit performed as expected at 6 pg/mL (121%). High levels
of IFNγ background were detected in the unspiked samples
using the Bio-Plex kit (49.2, 264.0 and 1193.7 pg/mL) com-
pared with background levels of 0.3, 4.5 and 6.7 pg/mL with
Fig. 1. Accuracy of spiked cytokine recovery. A and B—Human gastricmucosal
tissue homogenate supernatants were spiked with known concentrations of
recombinant interleukin-17A (IL-17, panel A) and interferon-gamma (IFNγ,
panel B), then cytokine concentrations assayed with different Luminex
kits (Bio-Plex and MILLIPLEX, VersaMAP excluded). Data were adjusted for
background using paired unspiked biopsies from the same patient, then
expected and observed concentrations plotted on a log–log scale. Expected
performance assuming 100% accuracy is shown by the dotted line. Error bars
were calculatedusing the coefficient of variation (%CV) for each sample fromall
bead fluorescence intensities between 5th centile and 95th centile (trimmed
bead %CV). No kits performed adequately b6 pg/mL. Although it under-reports
cytokine concentrations, the MILLIPLEX kit appears most consistent across the
two analytes for spikes of 6–1000 pg/mL. C — We compared manual and
automated tissue processing methods for four pairs of gastric mucosal biopsies
from four patients. Manual methods included all biopsies disrupted with a
pellet pestle with or without homogenisation using a needle and syringe.
Automated processing using a bead-basher (TissueLyser LT, QIAGEN). Accuracy
was calculated from percentage spiked cytokine recovery as [observed
concentration / expected concentration] × 100. The figure shows median and
inter-quartile range for each method, and comparisons using Mann–Whitney
U-tests.
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RPMI-1640 and FCS extraction buffer (A) yielded an IFNγ
reading of 1177.7 pg/mL with the Bio-Plex kit compared with
0.0 pg/mL for the PBS-based extraction buffers (B) and (C).
Since cytokine concentrations were to be normalised for
biopsy total protein, we proceeded with serum-free media
and therefore only extraction buffers (B) and (C) were used
to assess repeatability and compare processing methods.
3.3. Repeatability (intra-assay precision)
We measured the precision of Bio-Plex and MILLIPLEX in
quantifying spiked cytokine recovery across repeats of biolog-
ical replicates within each individual assay, which we report as
repeatability. Four identical aliquots of three different patient
samples were included at different positions on the same
plate. The coefficient of variation (%CV)was calculated for each
sample and amean %CV derived from the pooled %CV values. In
this analysis the %CVwas lowerwith theMILLIPLEX kit for IFNγ
(15.4% vs 39.3%) and with the Bio-Plex kit for IL-17 (15.6% vs
21.7%).
We also measured the intra-assay precision of these two
kits in quantifying cytokine concentrations derived from and
included in standard curve calculations. The pooled mean
%CV across all IL-17 standards was lower with the Bio-Plex kit
(11.8% vs 24.2%) and across all IFNγ standards was lower
with the MILLIPLEX kit (14.2% vs 25.1%). We have insufficient
data to report on inter-assay precision.
3.4. Comparison of processing methods
Complex biological samples derived from tissues have
not been evaluated by Luminex kit manufacturers and the
optimal procedure to prepare our human mucosal tissue
samples was not known. Determining the impact of different
protocols on cytokine measures could improve the utility of
Luminex-based methods to achieve our intended purpose —
namely the quantification of endogenous cytokines present
at low concentrations in small tissue samples. We compared
processing methods and extraction buffers for four pairs
of biopsies from each of four patients. Within each pair,
biopsies were spiked at 100 pg/mL or spiked with buffer
alone (“unspiked”), processed and then split into aliquots.
Manual sample disruption using a mini pellet pestle with
or without homogenisation using a needle and syringe,
and automated processing using a TissueLyser LT bead-basher
(QIAGEN) were compared, as detailed in Materials and
methods. Cytokine spikes were recovered significantly more
accurately from samples processed manually (Fig. 1C). There
were no significant differences between processingmethods in
relation to precision (data not shown) or total protein recovery
by BCA assay (mean ± SD for manual 821.8 ± 108.0 μg/mL vs
automated 800.3 ± 179.2 μg/mL).
We compared manual disruption using pestle alone with
additional homogenisation using needle and syringe. Spiked
cytokine recovery was usually lower with the latter (Table 2),
although this difference was not consistent or statistically
significant. We observed that homogenisation with a needle
and syringe leads to loss of sample volume, which was
retained in equipment dead space. In addition we evaluated
if the addition of benzonase to PBS-based extraction buffer
Table 2
Comparison of differentmanual processingmethods and addition of benzonase.
Gastric mucosal biopsies were spiked with 100 pg/mL of interleukin-17A
(IL-17) and interferon-gamma (IFNγ) prior to manual biopsy processing. Data
were adjusted for background using paired unspiked biopsies from the same
patient, andare equivalent to percentage spiked cytokine recovery. As described
in Materials and methods, we compared disruption in phosphate-buffered
saline (PBS)-based extraction buffer using a pellet pestle alone (n = 2),
disruption with homogenisation with a needle and syringe (n = 3), and
manual disruption/homogenisation in a PBS-based buffer which contained
benzonase (n = 2).
Median spiked cytokine recovery
(pg/mL)
Pestle + + +
Needle/syringe + +
Benzonase +
IL-17 Bio-Plex 56.0 50.8 67.6
MILLIPLEX 52.3 41.9 61.9
IFN-γ Bio-Plex 142.9 163.8 182.1
MILLIPLEX 55.1 40.9 69.6
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Benzonase is an endonuclease and digestion of nucleic acids
may reduce sample viscosity. There was a consistent trend for
increased cytokine recovery when benzonase was included
in the extraction buffer but these differences did not reach
statistical significance (Table 2).
3.5. Endogenous cytokines in clinical samples
To address the suitability of Luminex assays to detect
endogenous cytokines in clinical samples we tested unspiked
biopsies from uninfected and Hp-infected individuals using
our final sample homogenisation protocol (see Section 4.3)
for IL-17, IFNγ and also for IL-8, IL-4 and IL-10 using
MILLIPLEX kits (see Section 2.4 and Section 4.2).
We detected low background levels of IL-17, IFNγ and IL-8
in uninfected and uninflamed biopsies at or below the LLOQs
for these analytes (2.8, 2.4 and 0.1 pg/mL respectively).
However in Hp-infected biopsies there were marked 10 to 20
fold increases in IL-8 and IL-17 concentrations, and a smaller
increase for IFNγ that did not reach statistical significance
(Fig. 2A). These findings remained after correcting cytokine
concentration for total biopsy protein (Fig. 2B). We were
also able to detect differences in IL-10 in Hp-infected andFig. 2. Endogenous cytokine expression at protein and mRNA levels in
clinical samples. Levels of interleukin-17A (IL-17, IL17A), interferon-gamma
(IFNγ, IFNG) and IL-8 (IL8) in unspiked antral human gastric tissue biopsies
from patients infected with Helicobacter pylori (Hp+, X) and uninfected
subjects (Hp−, O). The figures show each data point with horizontal bar for
median value, fold-difference in medians between Hp+ and Hp−, and
comparisons using Mann–Whitney tests. A and B — Cytokine concentrations
were measured in clinical samples from 18 Hp+ and six Hp− subjects using
our selected Luminex kit and optimised tissue processing method (see
Sections 4.2 and 4.3), and reported unadjusted (panel A) and adjusted for
total biopsy protein (panel B). C — Cytokine mRNA expression was
determined using real-time reverse transcriptase polymerase chain reaction
(RT-qPCR) in a further 41 consecutive patients such that each transcript was
evaluated in 18 Hp+ and 6 Hp− patients as complete data were no
available for every patient. Results were analysed by Pfaffl's relative
quantification method (Pfaffl, 2001), normalising against GAPDH and
comparing against a pooled negative comparator prepared from a further
14 uninfected donors. Note that for figure clarity two data points were no
plotted— IL17A Hp+ 168.5 arbitrary units and IL8 Hp+ 111.6 arbitrary unitst
t
.uninfected tissues (median [inter-quartile range]; 10.0 pg/mg
protein [8.4–15.0] and 1.3 pg/mg protein [1.1–4.0] respectively,
p b 0.001, LLOQ3.5 pg/mL) and to detect IL-4 (Hp+:4.1 pg/mg
protein [2.8–4.7],Hp−: 6.3 pg/mgprotein [4.2–10.0], p = 0.08,
LLOQ 2.9 pg/mL). Relative cytokine yield was comparable to
7E. Staples et al. / Journal of Immunological Methods 394 (2013) 1–9mRNA expression quantified by RT-qPCR (Fig. 2C). The mean
pooled intra-assay %CV across all reported analytes for standard
curve cytokine measurements was 12.5% (7.3% for IL-17 and
12.1% for IFNγ).
4. Discussion
Our aim was the simultaneous quantification of multiple
cytokines present in human mucosal biopsies, which are
precious samples for translational researchers. Additional
challenges were the limited tissue sample size and the low
concentration of cytokines of interest in the healthy stomach.
Multi-parameter Luminex assays are an attractive option but
tissue samples are more complex than typical cell culture,
plasma and sera samples with which these assays were
developed. Ultimately our goal was an approach that would
more accurately assess the in vivo cytokine profile. We
evaluated the performance of three manufacturers' Luminex
assays for IL-17 and IFNγ in human gastric biopsies spiked
with recombinant cytokines and compared different ap-
proaches to sample preparation. We found that careful kit
selection and sample preparation can improve the quality of
data obtained from mucosal biopsies. Finally we assessed the
suitability of our optimised approach for detecting endoge-
nous cytokines.
4.1. Luminex kit performance — technical considerations and
standard curves
We identified greater bead aggregation and consequently
lower bead counts for the VersaMAP kit. This may in part be
due to the different software settings used to classify beads as
aggregates (DD gate). However the use of relatively viscous
tissue homogenates and vacuum washing may retain sample
matrix and clog the filter plate (Houser, 2012). Magnetic plate
washing of paramagnetic Luminex beads may be an advan-
tage for the analysis of tissue samples.
The MILLIPLEX kit had the advantage of requiring only
25 μL of sample per well, whereas for the VersaMAP and
Bio-Plex kits the manufacturers recommended 50 μL of
sample per well. In addition two further quality control vials
were included with the MILLIPLEX kit with expected ranges,
although these can only confirm standard curve integrity if
reconstituted and measured in the same matrix as samples
(Djoba Siawaya et al., 2008). The Bio-Plex kit was the fastest
assay to perform with the longest incubation time of only
30 min. Both the VersaMAP and MILLIPLEX kits required
incubations of 2 h after adding the samples then 1 h after
adding the biotinylated detection antibody.
Each kit recommended a different dilution series for the
standard curve: 3-fold 6-step for VersaMAP, 4-fold 8-step
for Bio-Plex and 5-fold 6-step for MILLIPLEX. Therefore
Luminex standard curves have a wider range than 2-fold
dilutions for a typical ELISA standard curve. This maximises
the number of wells available for samples andminimises the
need to test/retest for multiple cytokines at different
dilutions.
Finally it is important to consider analyte availability
and compatibility in selecting kit(s) from a particular
manufacturer.4.2. Luminex kit performance— sensitivity, accuracy and precision
We found that assay sensitivity varied between manufac-
turers and analytes, as other authors have observed (Khan
et al., 2004; duPont et al., 2005; Djoba Siawaya et al.,
2008; Breen et al., 2011). The MILLIPLEX kit performed
most consistently in our hands with a LLOQ ≤3.4 pg/mL and
the broadest linear dynamic range for both IL-17 and IFNγ.
No kits performed adequately with ≤1.5 pg/mL cytokine in
spike recovery experiments. Greater sensitivity and resolu-
tion at the lower end of standard curves might be achievable
by using the High RP1 target for instrument calibration
or by adjusting the weighting of logistic regression curve
fitting. Several manufacturers now market high-sensitivity/
ultrasensitive Luminex kits, currently for a more limited
number of analytes. These were recently investigated in a
study of serum cytokine concentrations (Breen et al., 2011).
Accuracy of cytokine spike recovery frequently fell outside
±25% of the expected values. However above the assay LLOQs
the trend generally followed that of the expected values,
even if the absolute values were different. Overall the
MILLIPLEX kit performed most consistently over the widest
range of spike concentrations, with spike recovery around one
third of expected. Internal similarity in relative values but
differences in absolute values have been noted in previous
studies comparing different Luminex kits and Luminex kits
with ELISA (Khan et al., 2004; Elshal and McCoy, 2006). In at
least partial explanation, a study by Nechansky et al. (2008)
compared cytokine standards from three commercial Luminex
kits to WHO standards, and demonstrated discrepant concen-
trations in some instances, concluding that the assays were not
fully quantitative. In addition although the samples, controls
and standards were prepared with identical extraction buffer,
the matrices differed as we did not, for example, pool multiple
biopsy homogenates for addition to standards and controls. For
researchers looking to report relative comparison of various
samples within a single patient cohort and research centre, our
approach may be acceptable provided that a single batch of
identical standards is used. Breen et al. (2011) reached similar
conclusions.
Our study identified imprecision as a potential important
limitation of Luminex assays. Repeatability in this study
showed high intra-assay %CV values (samples: 15–40%,
standards: ≤25%) compared with some published data on
Luminex kits (Biagini et al., 2004) but were consistent with
others (Djoba Siawaya et al., 2008). This imprecision may in
part be due to our repeated samples being closer to the LLOQ
of each kit, as we were particularly interested in kit sensitivity.
Subsequent evaluation of our final method showed improved
intra-assay precision for standards (b15%).
In summary, in our hands the MILLIPLEX kit delivered
most consistent spiked cytokine recovery (35–50% accuracy),
most consistent sensitivity at the lower limit of quantification,
the greatest linear dynamic range, the lowest rates of bead
aggregation and low bead counts, and the lowest sample
volume requirements. We therefore selected MILLIPLEX kits
for future studies, including high-sensitivity bead kits and use
of magnetic plate washing. Interestingly Serelli-Lee et al.
(2012) recently used MILLIPLEX assays to analyse mucosal
cytokine levels in human gastric biopsies, although used
traditional ELISA kits for IL-17 and IFNγ.
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We found that simple manual methods of disruption and
homogenisation were consistently superior to automated
methods with superior accuracy. This was unexpected but
may be the result of sample loss across the relatively large
surface area of the 5 mm beads used for automated processing
or from cytokine degradation. However we also observed that
homogenisation with a needle and syringe can lead to sample
loss in equipment dead space, which can be avoided by
aspiration into a pipette tip with similar orifice diameter. We
were restrained by sample availability for optimisation (four
pairs of biopsies each from four patients) so additional
methodological variables could not be empirically evaluated.
For example, a sonication-based approachwould need detailed
optimisation and, like rotor–stator homogenisation, has the
disadvantages of sample heating and the need for larger
extraction buffer volumes. We also avoided enzymatic, ionic
detergent and chemical methods in anticipation of potential
protein degradation and impacts on down-stream analysis.
This is supported by our finding that commercial protein
extraction kits were unsuitable, though others have used
non-ionic detergents with success (Luzza et al., 2000; Newton
et al., 2000).
When comparing cytokine concentrations in different
gastric biopsies it is necessary to control for biopsy size, as
opposed to comparisons of spike recovery from identical
aliquots of supernatant. Some authors investigating cytokine
concentrations in gastric biopsies have adjusted for biopsy
weight (Serelli-Lee et al., 2012), whereas others have taken the
approach of adjusting for total protein concentrationsmeasured
by either modified Lowry, Bradford or BCA assays (Crabtree
et al., 1991; Yamaoka et al., 2001; Hwang et al., 2002; Shimizu
et al., 2004; Queiroz et al., 2011). Similar to previous studies
(Kusugami et al., 1999), the gastric biopsies were small with
mean ±SD weight of 4.3 ± 2.9 mg (n = 18). Some re-
searchers use clinical samples prepared for analysis immedi-
ately after collection (Yamaoka et al., 2001). However as our
samples had been snap frozen they were associated with
variable amounts of water and mucus during thawing, so
weight was an unreliable measure of biopsy tissue content in
our hands. Therefore we used total biopsy protein by BCA assay
to normalise cytokine concentrations for biopsy size.
Optimisation of matrix/extraction buffer is also crucial for
complex samples such as tissue homogenates, which Luminex
kit manufacturers typically do not use when developing
and validating their assays. We selected PBS-based extraction
buffers without sera for our final method as we used BCA
assays to measure total biopsy protein. There is precedent for
the use of PBS-based buffers to assay cytokine concentrations
by ELISA in human gastric biopsies (Yamaoka et al., 2001;
Shimizu et al., 2004; Queiroz et al., 2011). We found a trend
towards the addition of endonuclease to the extraction buffer
increasing cytokine recovery though this did not reach
statistical significance. Initially we also found high background
readings for IFNγ with the Bio-Plex kit using the RPMI-1640
and FCS extraction buffer (A), and suspected that a component
of the media may have interfered with the assay. However
several studies have used similar matrices (duPont et al., 2005;
Djoba Siawaya et al., 2008; Richens et al., 2010; Serelli-Lee
et al., 2012). Some authors have reported matrix interactioneffects leading to a high level of background in Luminex assays
(Waterboer et al., 2006; Pickering et al., 2010). They overcame
this using additives to suppress non-specific binding or by
elimination of serum from their buffers and diluents.
Our final protocol after optimisation comprised: disruption
in 300 μL of buffer (C) with a pellet pestle on ice, homogeni-
sation by repeated aspiration into a 200 μL filter pipette tip
(Axygen, CA, USA) to minimise volume loss, incubation on
ice, centrifugation and division into aliquots for storage. One
aliquot was used to quantify total protein by BCA assay.
4.4. Suitability for detection of endogenous cytokines
IL-17, IFNγ, IL-8, IL-4 and IL-10 were measured in unspiked
gastric biopsies from 18 Hp-infected and six uninfected
patients using our selected Luminex kit and optimised sample
processing method to validate it for measurement of endoge-
nous cytokines. We were able to detect low background levels
of cytokines (with sensitivity of 0.1–3.5 pg/mL) and demon-
strate an increased concentration of endogenous cytokines in
disease, which were in keeping with mRNA expression data.
These findings are consistent with published data on relative
protein levels of these cytokines in Hp-infected and uninfected
patients measured by ELISA, western blotting and Luminex in
supernatants from gastric biopsy homogenate or gastric biopsy
culture (Bodger et al., 1997; Luzza et al., 2000; Shimizu et al.,
2004; Mizuno et al., 2005; Serelli-Lee et al., 2012).
5. Conclusions
Sensitive measurement of cytokine profiles using method-
ology that better reflects in vivo concentrations is technically
challenging. Optimisation of processing methods can improve
data acquisition from precious tissue samples. A number of
factors need to be considered when selecting an assay,
including the type and quantity of samples, the availability
and multiplexing capabilities of the desired analytes, the
expected range of concentrations and sensitivity required,
specificity, accuracy, precision, time and cost. We selected
Luminex assays fromMILLIPLEX for use in future studies based
on our evaluation findings. Together with our optimised
sample preparation protocol we concluded that Luminex
assays are a suitable technique for quantifying endogenous
cytokines in mucosal biopsies. We hope that our approach will
be more widely relevant for those seeking to quantify multiple
cytokines in small tissue samples.
Acknowledgements
The authors thank Dr Ian Spendlove, Dr Ann Lowe and
Prof Jan Bradley for use of their Bio-Plex 200 systems, Dr
Maria Toledo-Rodriguez for use of her TissueLyser LT, and
the patients and staff at Nottingham University Hospital.
We purchased all kits used in this study. The study design,
collection, analysis and interpretation of data, writing of the
report and decision to submit for publication were under-
taken independently by the authors without involvement of
the funders or kit manufacturers.
ES and RI are supported by Clinical Research Training
Fellowships from the Medical Research Council [grant
numbers G0701377 and G1000311]. This article presents
9E. Staples et al. / Journal of Immunological Methods 394 (2013) 1–9independent research supported by the National Institute
for Health Research (NIHR), through the NIHR Biomedical
Research Unit in Gastrointestinal and Liver Diseases at
Nottingham University Hospitals NHS Trust and the Univer-
sity of Nottingham. The views expressed are those of the
author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
References
Atherton, J.C., 2006. The pathogenesis of Helicobacter pylori-induced gastro-
duodenal diseases. Annu. Rev. Pathol. 1, 63.
Biagini, R.E., Sammons, D.L., Smith, J.P., MacKenzie, B.A., Striley, C.A.F.,
Semenova, V., Steward-Clark, E., Stamey, K., Freeman, A.E., Quinn, C.P.,
Snawder, J.E., 2004. Comparison of a multiplexed fluorescent covalent
microsphere immunoassay and an enzyme-linked immunosorbent
assay for measurement of human immunoglobulin G antibodies to
anthrax toxins. Clin. Diagn. Lab. Immunol. 11, 50.
Bodger, K., Wyatt, J.I., Heatley, R.V., 1997. Gastric mucosal secretion of
interleukin-10: relations to histopathology, Helicobacter pylori status,
and tumour necrosis factor-alpha secretion. Gut 40, 739.
Breen, E.C., Reynolds, S.M., Cox, C., Jacobson, L.P., Magpantay, L., Mulder, C.B.,
Dibben, O., Margolick, J.B., Bream, J.H., Sambrano, E., Martínez-Maza, O.,
Sinclair, E., Borrow, P., Landay, A.L., Rinaldo, C.R., Norris, P.J., 2011.
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin.
Vaccine Immunol. 18, 1229.
Caruso, R., Fina, D., Paoluzi, O.A., Blanco, G.D.V., Stolfi, C., Rizzo, A., Caprioli, F.,
Sarra, M., Fabio, A., Fantini, M.C., MacDonald, T.T., Pallone, F., Monteleone,
G., 2008. IL-23-mediated regulation of IL-17 production in Helicobacter
pylori-infected gastric mucosa. Eur. J. Immunol. 38, 470.
Crabtree, J.E., Shallcross, T.M., Heatley, R.V., Wyatt, J.I., 1991. Mucosal tumour
necrosis factor alpha and interleukin-6 in patients with Helicobacter
pylori associated gastritis. Gut 32, 1473.
Djoba Siawaya, J.F., Roberts, T., Babb, C., Black, G., Golakai, H.J., Stanley, K.,
Bapela, N.B., Hoal, E., Parida, S., van Helden, P., Walzl, G., 2008. An
evaluation of commercial fluorescent bead-based luminex cytokine assays.
PLoS One 3, e2535.
duPont, N.C., Wang, K., Wadhwa, P.D., Culhane, J.F., Nelson, E.L., 2005.
Validation and comparison of luminex multiplex cytokine analysis kits
with ELISA: determinations of a panel of nine cytokines in clinical
sample culture supernatants. J. Reprod. Immunol. 66, 175.
Elshal, M.F., McCoy, J.P., 2006. Multiplex bead array assays: performance
evaluation and comparison of sensitivity to ELISA. Methods 38, 317.
Griffin, S.M., Chen, I.M., Fout, G.S., Wade, T.J., Egorov, A.I., 2011. Development
of a multiplex microsphere immunoassay for the quantitation of salivary
antibody responses to selected waterborne pathogens. J. Immunol.
Methods 364, 83.
Holck, S., Nørgaard, A., Bennedsen, M., Permin, H., Norn, S., Andersen, L.P.,
2003. Gastric mucosal cytokine responses in Helicobacter pylori-infected
patients with gastritis and peptic ulcers. Association with inflammatory
parameters and bacteria load. FEMS Immunol. Med. Microbiol. 36, 175.
Houser, B., 2012. Bio-Rad's Bio-Plex® suspension array system, xMAP
technology overview. Arch. Physiol. Biochem. 118, 192.
Hwang, I.-R., Kodama, T., Kikuchi, S., Sakai, K., Peterson, L.E., Graham, D.Y.,
Yamaoka, Y., 2002. Effect of interleukin 1 polymorphisms on gastric
mucosal interleukin 1beta production in Helicobacter pylori infection.
Gastroenterology 123, 1793.
Khan, S.S., Smith, M.S., Reda, D., Suffredini, A.F., McCoy, J.P., 2004. Multiplex
bead array assays for detection of soluble cytokines: comparisons of
sensitivity and quantitative values among kits from multiple manufac-
turers. Cytometry B Clin. Cytom. 61, 35.
Kusugami, K., Ando, T., Imada, A., Ina, K., Ohsuga, M., Shimizu, T., Sakai, T.,
Konagaya, T., Kaneko, H., 1999. Mucosal macrophage inflammatory
protein-1alpha activity in Helicobacter pylori infection. J. Gastroenterol.
Hepatol. 14, 20.
Lehmann, F.S., Terracciano, L., Carena, I., Baeriswyl, C., Drewe, J., Tornillo, L.,
De Libero, G., Beglinger, C., 2002. In situ correlation of cytokine secretion
and apoptosis in Helicobacter pylori-associated gastritis. Am. J. Physiol.
Gastrointest. Liver Physiol. 283, G481.Lindholm, C., Quiding-Järbrink, M., Lönroth, H., Hamlet, A., Svennerholm,
A.M., 1998. Local cytokine response inHelicobacter pylori-infected subjects.
Infect. Immun. 66, 5964.
Luzza, F., Parrello, T., Monteleone, G., Sebkova, L., Romano, M., Zarrilli, R.,
Imeneo, M., Pallone, F., 2000. Up-regulation of IL-17 is associated with
bioactive IL-8 expression in Helicobacter pylori-infected human gastric
mucosa. J. Immunol. 165, 5332.
Luzza, F., Parrello, T., Sebkova, L., Pensabene, L., Imeneo, M., Mancuso, M., La
Vecchia, A.M., Monteleone, G., Strisciuglio, P., Pallone, F., 2001. Expression
of proinflammatory and Th1 but not Th2 cytokines is enhanced in gastric
mucosa of Helicobacter pylori infected children. Dig. Liver Dis. 33, 14.
Mizuno, T., Ando, T., Nobata, K., Tsuzuki, T., Maeda, O., Watanabe, O., Minami,
M., Ina, K., Kusugami, K., Peek, R.M., Goto, H., 2005. Interleukin-17 levels
in Helicobacter pylori-infected gastric mucosa and pathologic sequelae
of colonization. World J. Gastroenterol. 11, 6305.
Nechansky, A., Grunt, S., Roitt, I.M., Kircheis, R., 2008. Comparison of the
calibration standards of three commercially available multiplex kits
for human cytokine measurement to WHO standards reveals striking
differences. Biomark. Insights 3, 227.
Newton, J.L., Allen, A., Westley, B.R., May, F.E., 2000. The human trefoil
peptide, TFF1, is present in different molecular forms that are intimately
associated with mucus in normal stomach. Gut 46, 312.
Pfaffl, M.W., 2001. A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res. 29, e45.
Pickering, J.W., Larson, M.T., Martins, T.B., Copple, S.S., Hill, H.R., 2010.
Elimination of false-positive results in a luminex assay for pneumococcal
antibodies. Clin. Vaccine Immunol. 17, 185.
Queiroz, D.M., Rocha, G.A., Rocha, A.M., Moura, S.B., Saraiva, I.E., Gomes, L.I.,
Soares, T.F., Melo, F.F., Cabral, M.M., Oliveira, C.A., 2011. dupA poly-
morphisms and risk of Helicobacter pylori-associated diseases. Int. J. Med.
Microbiol. 301, 225.
Richens, J.L., Urbanowicz, R.A., Metcalf, R., Corne, J., O'Shea, P., Fairclough, L.,
2010. Quantitative validation and comparison of multiplex cytokine kits.
J. Biomol. Screen. 15, 562.
Robinson, K., Kenefeck, R., Pidgeon, E.L., Shakib, S., Patel, S., Polson, R.J.,
Zaitoun, A.M., Atherton, J.C., 2008. Helicobacter pylori-induced peptic
ulcer disease is associated with inadequate regulartory T cell responses.
Gut 57, 1375.
Schumacher, M.A., Donnelly, J.M., Engevik, A.C., Xiao, C., Yang, L., Kenny, S.,
Varro, A., Hollande, F., Samuelson, L.C., Zavros, Y., 2012. Gastric Sonic
Hedgehog acts as a macrophage chemoattractant during the immune
response to Helicobacter pylori. Gastroenterology 142, 1150.
Serelli-Lee, V., Ling, K.L., Ho, C., Yeong, L.H., Lim, G.K., Ho, B., Wong, S.B.J.,
2012. Persistent Helicobacter pylori specific Th17 responses in patients
with past H. pylori infection are associated with elevated gastric mucosal
IL-1β. PLoS One 7, e39199.
Shimizu, T., Haruna, H., Ohtsuka, Y., Kaneko, K., Gupta, R., Yamashiro, Y.,
2004. Cytokines in the gastric mucosa of children with Helicobacter pylori
infection. Acta Paediatr. 93, 322.
Taylor, J.M., Ziman, M.E., Fong, J., Solnick, J.V., Vajdy, M., 2007. Possible
correlates of long-term protection against Helicobacter pylori following
systemic or combinations of mucosal and systemic immunizations.
Infect. Immun. 75, 3462.
Taylor, J.M., Ziman, M.E., Canfield, D.R., Vajdy, M., Solnick, J.V., 2008. Effects
of a Th1- versus a Th2-biased immune response in protection against
Helicobacter pylori challenge in mice. Microb. Pathog. 44, 20.
Tomita, T., Jackson, A.M., Hida, N., Hayat, M., Dixon, M.F., Shimoyama, T.,
Axon, A.T., Robinson, P.A., Crabtree, J.E., 2001. Expression of Interleukin-
18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter
pylori infection. J. Infect. Dis. 183, 620.
Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., Stockinger, B., 2009.
Natural agonists for aryl hydrocarbon receptor in culture medium are
essential for optimal differentiation of Th17 T cells. J. Exp. Med. 206, 43.
Vignali, D.A.A., 2000. Multiplexed particle-based flow cytometric assays.
J. Immunol. Methods 243, 243.
Waterboer, T., Sehr, P., Pawlita, M., 2006. Suppression of non-specific
binding in serological Luminex assays. J. Immunol. Methods 309, 200.
Yamaoka, Y., Kodama, T., Kita, M., Imanishi, J., Kashima, K., Graham, D.Y.,
2001. Relation between cytokines and Helicobacter pylori in gastric cancer.
Helicobacter 6, 116.
